FeesSafety
Pluang+

Satlyt raises $8M to launch AI software for satellites, enabling shared computing in space.

Market News
01 Oct 2026
TechCrunch
View Source
Bullish
Satlyt raises $8M to launch AI software for satellites, enabling shared computing in space.

Satlyt, co-founded by former Google and SpaceX engineer Rama Afullo, has raised $8 million to develop software that enables satellites to share computing tasks in orbit. Unlike companies building physical space data centers, Satlyt focuses on AI software that improves satellite efficiency by processing data onboard, reducing costly data transmissions to Earth. Their software will soon launch on a SpaceX rocket with customers including NASA and startups testing space cloud computing and image processing. Satlyt aims to create a shared computing cloud across satellites, potentially transforming satellite operations and generating new revenue streams by 2030.

Satlyt's recent $8 million funding round for AI satellite software provides context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Oct 01, 2026 17:51 WIB: Out of 150 priced US technology stocks tradable on Pluang, 121 rose and 23 fell today. Notable movers include INFY at USD 11.34 with a 5.39% increase and 100% buy order activity, EPAM at USD 113.54 up 4.78%, and IT at USD 195.00 rising 4.54%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
46 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
46 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
46 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App